John Armitage
Egerton Capital
John Armitage CME Group Inc stake
total: 222
Egerton Capital CME trades
- Total transactions:
- 10
- New positions:
- 2
- Sold out:
- 2
- Added:
- 2
- Reduced:
- 4
- Held since:
- 2024 Q4
- Held for:
- 6 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, John Armitage doesn't hold any CME Group Inc (CME) shares. To date, the estimated cost basis is nearly $246.95 for "buy" trades and estimated average "sell" price is $288.02. Egerton Capital first purchased CME in 2020 Q4, initially acquiring 450,249 shares. John Armitage later completely sold out the position and invested in CME Group Inc again in 2024 Q4. Since the initial investment in CME Group Inc (CME), Egerton Capital has made 9 more transactions.
When did John Armitage sell CME Group Inc (CME)?
John Armitage sold off the entire CME Group Inc (CME) position in 2026 Q2.
When did John Armitage buy CME Group Inc (CME)?
John Armitage first invested in CME Group Inc (CME) in 2020 Q4 at the reported quarter-end price of $182.05 per share.
What's the cost basis of Egerton Capital's CME stake?
The estimated cost basis for CME Group Inc (CME) stake is around $246.95 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $246.95
- Weighted AVG sell price:
- $288.02
John Armitage's historical trades in CME Group Inc
10 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.00%
|
0
|
$295.35
|
|
-100% (-1,182,907)
|
-3.88%
|
|
2026 Q1
|
3.88%
|
1,182,907
|
$295.35
|
$349,371,582
|
+0.26% (+3,115)
|
+0.01%
|
|
2025 Q4
|
3.50%
|
1,179,792
|
$273.08
|
$322,177,599
|
-0.42% (-4,996)
|
-0.01%
|
|
2025 Q3
|
3.38%
|
1,184,788
|
$270.19
|
$320,117,870
|
-22.20% (-338,148)
|
-0.94%
|
|
2025 Q2
|
4.31%
|
1,522,936
|
$275.62
|
$419,751,620
|
-11.98% (-207,258)
|
-0.66%
|
|
2025 Q1
|
5.30%
|
1,730,194
|
$265.29
|
$459,003,166
|
+79.40% (+765,773)
|
+2.34%
|
|
2024 Q4
|
2.59%
|
964,421
|
$232.23
|
$223,967,489
|
new
|
+2.59%
|
|
2021 Q2
|
0.00%
|
0
|
$204.23
|
|
-100% (-449,800)
|
-0.48%
|
|
2021 Q1
|
0.48%
|
449,800
|
$204.23
|
$91,863,000
|
-0.10% (-449)
|
-0%
|
|
2020 Q4
|
0.46%
|
$182.05
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.